Methanaminium, N-((dimethylamino)(3H-1,2,3-triazolo(4,5-b)pyridin-3-yloxy)methylene)-N-methyl-, hexafluorophosphate(1-) (1:1) → HCID 67682560, compound

HRID 1751717Notes

Reaction equation

HRID 1751717 reaction equation
[CH3:1][O:2][CH2:3][C@@H:4]1[CH2:8][NH:7][C@H:6]([C:9]2[NH:10][C:11]([C:14]3[CH:27]=[C:26]4[O:28][CH2:29][C:23]5[C:24]6[C:25]4=[C:16]([CH2:17][O:18][C:19]=6[CH:20]=[C:21]([C:30]4[NH:34][C:33]([C@@H:35]6[CH2:39][C@H:38]([CH3:40])[CH2:37][N:36]6[C:41](=[O:54])[C@H:42]([NH:49][C:50](=[O:53])[O:51][CH3:52])[C:43]6[CH:48]=[CH:47][CH:46]=[CH:45][CH:44]=6)=[N:32][CH:31]=4)[CH:22]=5)[CH:15]=3)=[CH:12][N:13]=2)[CH2:5]1.[CH3:55][O:56][C:57]([NH:59][C@@H:60]([CH:64]([CH3:66])[CH3:65])[C:61](O)=[O:62])=[O:58].CN(C(ON1N=NC2C=CC=NC1=2)=[N+](C)C)C.F[P-](F)(F)(F)(F)F>CCN(C(C)C)C(C)C.CN(C=O)C>[CH3:55][O:56][C:57]([NH:59][C@@H:60]([CH:64]([CH3:66])[CH3:65])[C:61]([N:7]1[CH2:8][C@@H:4]([CH2:3][O:2][CH3:1])[CH2:5][C@H:6]1[C:9]1[NH:10][C:11]([C:14]2[CH:15]=[C:16]3[CH2:17][O:18][C:19]4[C:24]5=[C:23]([CH:22]=[C:21]([C:30]6[NH:34][C:33]([C@@H:35]7[CH2:39][C@H:38]([CH3:40])[CH2:37][N:36]7[C:41](=[O:54])[C@H:42]([NH:49][C:50]([O:51][CH3:52])=[O:53])[C:43]7[CH:44]=[CH:45][CH:46]=[CH:47][CH:48]=7)=[N:32][CH:31]=6)[CH:20]=4)[CH2:29][O:28][C:26]([CH:27]=2)=[C:25]35)=[CH:12][N:13]=1)=[O:62])=[O:58]

Participants

6

Reactant 3

HCID 9886157Methanaminium, N-((dimethylamino)(3H-1,2,3-triazolo(4,5-b)pyridin-3-yloxy)methylene)-N-methyl-, hexafluorophosphate(1-) (1:1)2×HCID 10942966(2S)-2-((methoxycarbonyl)amino)-3-methylbutanoic acid2×HCID 86708810HCID 86708810, compound

Product 1

HCID 67682560HCID 67682560, compound

Reagents, catalysts & solvents 2

HCID 6228DimethylformamideSolventHCID 81531DiisopropylethylamineSolvent

Procedure

A mixture of methyl (R)-2-((2S,4S)-2-(5-(7-(2-((2S,4S)-4-(methoxymethyl)pyrrolidin-2-yl)-1H-imidazol-5-yl)-5,10-dihydrochromeno[5,4,3-cde]chromen-2-yl)-1H-imidazol-2-yl)-4-methylpyrrolidin-1-yl)-2-oxo-1-phenylethylcarbamate (90 mg, >0.123 mmol), (S)-2-(methoxycarbonylamino)-3-methylbutanoic acid (24 mg, 0.135 mmol), HATU (51 mg, 0.135 mmol) in 1.5 mL 10% DIPEA in DMF was stirred for 1 hour. An additional 0.135 mmol of (S)-2-(methoxycarbonylamino)-3-methylbutanoic acid and HATU were added and stirring continued for 4 hours. The crude product was purified by reverse phase HPLC to product (28 mg) as a trifluoroacetate salt.

Workup

  1. stirringstirring
  2. waitcontinued for 4 hours
  3. customThe crude product was purified by reverse phase HPLC to product (28 mg) as a trifluoroacetate salt

Sources & evidence

ORD record
ord-35e6aea3d4844eac83b73bdfe1885386
Source dataset
uspto-grants-2015_10
Patent number
US09156823B2

Reaction notes

Loading…